葡萄糖胺酶用于治疗高剂量甲醇毒性
Shruti Gupta1,2,3, Sarah A Kaunfer1, Kevin L Chen4
1Division of Renal Medicine, Brigham and Women's Hospital, Boston, MA.
Blood
|January 6, 2025
概括
在高剂量甲状腺诱导的急性损伤 (MTX-AKI) 患者中,葡萄糖剂的使用显著改善了的恢复,并减少了中性衰竭和肝毒性. 这种酶可能为管理MTX毒性提供一种有价值的治疗选择.
科学领域:
- 在瘤学瘤学.
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 高剂量甲状腺素 (MTX) 治疗与急性损伤 (AKI),中性质衰竭和肝毒性的显著风险有关.
- 葡萄糖酶,一种分裂MTX的酶,具有有限的临床数据支持其在缓解MTX相关毒性的有效性.
- 了解MTX诱导的AKI (MTX-AKI) 患者中葡萄糖酶的实际有效性对于临床决策至关重要.
研究的目的:
- 评估在接受MTX-AKI的成年患者中葡萄糖酶的使用与临床结果之间的关联.
- 评估葡萄糖酶对脏恢复,恢复时间,中性质减退,透氨酸炎和死亡率的影响.
主要方法:
- 使用来自美国28个癌症中心的数据,采用了一种序列向试验仿真框架.
- 多变量后勤和考克斯回归模型被用来比较在MTX开始后4天内接受葡萄糖酶的患者和没有接受葡萄糖酶的患者之间的结果.
- 主要终点是医院出院时脏的恢复;次要终点包括恢复时间,中性质减退,膜炎和死亡.
主要成果:
- 在708名MTX-AKI患者中,209名 (29.5%) 接受了葡萄糖酶.
- 葡萄糖剂的接收与脏恢复的几率增加了2.70倍 (95% CI,1.69-4.31) 和更快的恢复时间 (aHR,1.88;95% CI,1.18-3.33).
- 用葡萄糖酶治疗的患者在第7天也显示了≥2级中性质衰竭 (aOR,0.50;95% CI,0.28-0.91) 和≥2级透氨炎 (aOR,0.50;95% CI,0.28-0.91) 的风险降低,死亡时间没有显著差异.
结论:
- 在患有MTX-AKI的患者中,葡萄糖剂的使用似乎可以改善的恢复,并减少外毒性,如中性质衰竭和透氨酸炎.
- 这些发现表明,葡萄糖酶可能是一种有益的辅助疗法,用于管理高剂量甲醇毒性.
- 需要进一步的前性研究来证实这些益处,并建立最佳使用准则.
相关概念视频
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
01:23Dipeptidyl Peptidase 4 Inhibitors
166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166
01:17Phase II Reactions: Methylation Reactions
131
Methylation is a phase II biotransformation process involving the attachment of a methyl group to a substrate. Enzymes known as methyltransferases orchestrate this reaction.
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
The mechanism of methylation unfolds in two stages. The first stage sees a methyltransferase enzyme facilitating the transfer of a methyl group from S-adenosylmethionine (SAM) to the substrate, forming S-adenosylhomocysteine (SAH). The second stage involves further metabolism of SAH into homocysteine, which can be recycled...
131